StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research note issued to investors on Thursday morning. The brokerage issued a buy rating on the biotechnology company’s stock.
Several other equities research analysts have also issued reports on ADAP. Mizuho dropped their price objective on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. HC Wainwright dropped their price target on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, Guggenheim dropped their price target on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Adaptimmune Therapeutics presently has an average rating of “Buy” and an average price target of $2.79.
View Our Latest Stock Analysis on Adaptimmune Therapeutics
Adaptimmune Therapeutics Price Performance
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of ADAP. GSA Capital Partners LLP purchased a new position in shares of Adaptimmune Therapeutics in the third quarter worth about $95,000. FMR LLC increased its holdings in Adaptimmune Therapeutics by 3.0% during the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after purchasing an additional 50,419 shares during the period. Jane Street Group LLC increased its holdings in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 98,581 shares during the period. Virtu Financial LLC increased its holdings in Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 21,769 shares during the period. Finally, LPL Financial LLC increased its holdings in Adaptimmune Therapeutics by 106.5% during the 4th quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 94,623 shares during the period. Hedge funds and other institutional investors own 31.37% of the company’s stock.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Read More
- Five stocks we like better than Adaptimmune Therapeutics
- How to Choose Top Rated Stocks
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Consumer Discretionary Stocks Explained
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.